Steve Duffy

Digital Content Editor

Most Recent Articles by Steve Duffy

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

By

Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

Firdapse NDA Submitted for Lambert-Eaton Myasthenic Syndrome

By

Results from the Phase 3 trial showed that the Quantitative Myasthenia Gravis (QMG) score at baseline to day 14 changed from 6.4 to 6.7 in the amifampridine group vs. 5.6 to 7.9 for the placebo group.

FDA Fast Tracks Treatment for Fragile X Syndrome

FDA Fast Tracks Treatment for Fragile X Syndrome

By

OV101 has previously been granted Orphan Drug status for Fragile X and Fast Track status for Angelman syndrome.

NDA for Inhaled Levodopa Therapy for Parkinson's Accepted by FDA

NDA for Inhaled Levodopa Therapy for Parkinson's Accepted by FDA

By

The SPAN-PD trial found that Inbrija 84mg improved motor functions in Parkinson Disease experiencing off periods.

FDA Approves Smart Watch for Epilepsy Management

FDA Approves Smart Watch for Epilepsy Management

By

The FDA has cleared the Embrace smart watch for managing epilepsy.

More Articles by Steve Duffy

Sign Up for Free e-newsletters

CME Focus